University of Pennsylvania

ScholarlyCommons
Departmental Papers (Vet)

School of Veterinary Medicine

6-26-2007

Canine and Human Visual Cortex Intact and Responsive Despite
Early Retinal Blindness from RPE65 Mutation
Geoffrey K. Aguirre
University of Pennsylvania, aguirreg@mail.med.upenn.edu

András M. Komáromy
University of Pennsylvania, komaromy@vet.upenn.edu

Artur V. Cideciyan
University of Pennsylvania, cideciya@mail.med.upenn.edu

David H. Brainard
University of Pennsylvania, brainard@psych.upenn.edu

Tomas S. Aleman
University of Pennsylvania, aleman@mail.med.upenn.edu

See next page for additional authors
Follow this and additional works at: https://repository.upenn.edu/vet_papers
Part of the Comparative and Laboratory Animal Medicine Commons, Congenital, Hereditary, and
Neonatal Diseases and Abnormalities Commons, Eye Diseases Commons, and the Ophthalmology
Commons

Recommended Citation
Aguirre, G. K., Komáromy, A. M., Cideciyan, A. V., Brainard, D. H., Aleman, T. S., Roman, A. J., Avants, B. B.,
Gee, J. C., Korczykowski, M., Hauswirth, W. W., Acland, G. M., Aguirre, G. D., & Jacobson, S. G. (2007).
Canine and Human Visual Cortex Intact and Responsive Despite Early Retinal Blindness from RPE65
Mutation. PLoS Medicine, 4 (6), e230-. http://dx.doi.org/10.1371/journal.pmed.0040230

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/vet_papers/27
For more information, please contact repository@pobox.upenn.edu.

Canine and Human Visual Cortex Intact and Responsive Despite Early Retinal
Blindness from RPE65 Mutation
Abstract
Background
RPE65 is an essential molecule in the retinoid-visual cycle, and RPE65 gene mutations cause the
congenital human blindness known as Leber congenital amaurosis (LCA). Somatic gene therapy delivered
to the retina of blind dogs with an RPE65 mutation dramatically restores retinal physiology and has
sparked international interest in human treatment trials for this incurable disease. An unanswered
question is how the visual cortex responds after prolonged sensory deprivation from retinal dysfunction.
We therefore studied the cortex of RPE65-mutant dogs before and after retinal gene therapy. Then, we
inquired whether there is visual pathway integrity and responsivity in adult humans with LCA due to
RPE65 mutations (RPE65-LCA).
Methods and Findings

RPE65-mutant dogs were studied with fMRI. Prior to therapy, retinal and subcortical responses to light
were markedly diminished, and there were minimal cortical responses within the primary visual areas of
the lateral gyrus (activation amplitude mean ± standard deviation [SD] = 0.07% ± 0.06% and volume = 1.3
± 0.6 cm3). Following therapy, retinal and subcortical response restoration was accompanied by
increased amplitude (0.18% ± 0.06%) and volume (8.2 ± 0.8 cm3) of activation within the lateral gyrus (p <
0.005 for both). Cortical recovery occurred rapidly (within a month of treatment) and was persistent (as
long as 2.5 y after treatment). Recovery was present even when treatment was provided as late as 1–4 y
of age. Human RPE65-LCA patients (ages 18–23 y) were studied with structural magnetic resonance
imaging. Optic nerve diameter (3.2 ± 0.5 mm) was within the normal range (3.2 ± 0.3 mm), and occipital
cortical white matter density as judged by voxel-based morphometry was slightly but significantly altered
(1.3 SD below control average, p = 0.005). Functional magnetic resonance imaging in human RPE65-LCA
patients revealed cortical responses with a markedly diminished activation volume (8.8 ± 1.2 cm3)
compared to controls (29.7 ± 8.3 cm3, p < 0.001) when stimulated with lower intensity light. Unexpectedly,
cortical response volume (41.2 ± 11.1 cm3) was comparable to normal (48.8 ± 3.1 cm3, p = 0.2) with
higher intensity light stimulation.
Conclusions
Visual cortical responses dramatically improve after retinal gene therapy in the canine model of
RPE65-LCA. Human RPE65-LCA patients have preserved visual pathway anatomy and detectable cortical
activation despite limited visual experience. Taken together, the results support the potential for human
visual benefit from retinal therapies currently being aimed at restoring vision to the congenitally blind with
genetic retinal disease.
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RPE65 is an essential molecule in the retinoid-visual cycle, and RPE65 gene mutations cause
the congenital human blindness known as Leber congenital amaurosis (LCA). Somatic gene
therapy delivered to the retina of blind dogs with an RPE65 mutation dramatically restores
retinal physiology and has sparked international interest in human treatment trials for this
incurable disease. An unanswered question is how the visual cortex responds after prolonged
sensory deprivation from retinal dysfunction. We therefore studied the cortex of RPE65-mutant
dogs before and after retinal gene therapy. Then, we inquired whether there is visual pathway
integrity and responsivity in adult humans with LCA due to RPE65 mutations (RPE65-LCA).

Methods and Findings
RPE65-mutant dogs were studied with fMRI. Prior to therapy, retinal and subcortical
responses to light were markedly diminished, and there were minimal cortical responses within
the primary visual areas of the lateral gyrus (activation amplitude mean 6 standard deviation
[SD] ¼ 0.07% 6 0.06% and volume ¼ 1.3 6 0.6 cm3). Following therapy, retinal and subcortical
response restoration was accompanied by increased amplitude (0.18% 6 0.06%) and volume
(8.2 6 0.8 cm3) of activation within the lateral gyrus (p , 0.005 for both). Cortical recovery
occurred rapidly (within a month of treatment) and was persistent (as long as 2.5 y after
treatment). Recovery was present even when treatment was provided as late as 1–4 y of age.
Human RPE65-LCA patients (ages 18–23 y) were studied with structural magnetic resonance
imaging. Optic nerve diameter (3.2 6 0.5 mm) was within the normal range (3.2 6 0.3 mm),
and occipital cortical white matter density as judged by voxel-based morphometry was slightly
but significantly altered (1.3 SD below control average, p ¼ 0.005). Functional magnetic
resonance imaging in human RPE65-LCA patients revealed cortical responses with a markedly
diminished activation volume (8.8 6 1.2 cm3) compared to controls (29.7 6 8.3 cm3, p , 0.001)
when stimulated with lower intensity light. Unexpectedly, cortical response volume (41.2 6
11.1 cm3) was comparable to normal (48.8 6 3.1 cm3, p ¼ 0.2) with higher intensity light
stimulation.

Conclusions
Visual cortical responses dramatically improve after retinal gene therapy in the canine model
of RPE65-LCA. Human RPE65-LCA patients have preserved visual pathway anatomy and
detectable cortical activation despite limited visual experience. Taken together, the results
support the potential for human visual benefit from retinal therapies currently being aimed at
restoring vision to the congenitally blind with genetic retinal disease.
The Editors’ Summary of this article follows the references.
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Introduction
Table 1. Dogs Studied with fMRI
The childhood-onset incurable human retinal blindness
termed Leber congenital amaurosis (LCA) has become a
target for in vivo gene transfer because of remarkable success
in animal models of several molecular forms [1–5]. The most
studied form of LCA is that due to mutations in RPE65
(RPE65-LCA), the critical retinoid (visual) cycle gene that
encodes the isomerohydrolase in retinal pigment epithelium
(RPE) cells [6,7]. Physiological and biochemical recovery at
the level of the retina of RPE65-deﬁcient dogs and mice is
dramatic after a single viral-mediated transfer of the RPE65
gene (for example, [1,2,8,9]). Far less information is available
on the details of recovery in postretinal visual pathways [10],
and especially cortical visual function [1,11].
Many issues have been addressed during preparation for
human ocular gene therapy clinical trials in RPE65-LCA
patients [12–14], but we remain uncertain about the recovery
potential of the visual cortex after prolonged and severe
visual deprivation from this congenital retinal defect. The
current study addresses this uncertainty with experiments in
RPE65-mutant dogs and in human RPE65-LCA patients.
Blood oxygen level–dependent (BOLD) functional magnetic
resonance imaging (fMRI) is used to determine if cortical
responses to visual stimulation are restored in previously
blind RPE65-mutant dogs following retinal gene therapy.
The complementary and answerable question prior to
human gene therapy in RPE65-LCA patients is whether
affected individuals have intact visual pathways leading from
the defective retina to the visual cortex. Reports of earlyonset blind individuals have shown altered visual pathway
anatomy [15–17]. To determine the receptivity of cortical
substrates for restored retinal input, we evaluated the
structure and function of the visual pathways from retina
to cortex of young adults with LCA caused by RPE65
mutations.

Dogs

Normal

—
—
RPE65-mutant Subtherapeutic
Therapeutic
Therapeutic
Therapeutic
Therapeutic
Therapeutic

Animal Age at
Treatment Age at
Code
Treatment Durationa MRI
(Years)
(Years)
E946
EMB9
BR239b
BR235b,c
BR164
BR174
BR58
BR57b

—
—
,1
,1
,1
,1
1
4

—
—
Short
Short
Long
Long
Long
Short

2
2
,1
,1
2
2
3
4

a

Short, 1–3 mo; long, 18–30 mo.
fMRI data also acquired pretreatment.
Two post-treatment fMRI studies performed.
doi:10.1371/journal.pmed.0040230.t001
b
c

(10 lV) b-wave; the amplitude parameter was deﬁned as bwave amplitude in response to a 2.2 log scot-cd.s.m2
stimulus.

Transient Pupillary Light Reflex
The direct transient pupillary light reﬂex (TPLR) was
recorded as published [1,10]. TPLR luminance-response
functions were elicited with short-duration (0.1 s) stimuli of
increasing intensity (green, 6.6 to 2.3 log scot-cd.m2; white,
2.53 log scot-cd.m2); comparisons were made using threshold
and amplitude parameters. TPLR threshold was deﬁned as
the stimulus intensity that evoked a criterion (0.4 mm)
contraction of the pupil diameter (at 0.6 s); TPLR amplitude
was deﬁned as the contraction of the pupil diameter (at 0.6 s)
elicited by a 0.6 log scot-cd.m2 green stimulus.

BOLD fMRI Scanning
Prior to scanning, pupils were dilated (topical 1% atropine,
1% tropicamide, and 10% phenylephrine). Anesthesia was
with IV ketamine (10 mg/kg) and diazepam (0.28 mg/kg)
following SQ atropine (0.05 mg/kg). The anesthetic regimen is
comparable to that used for ERG acquisition and preserves
optokinetic responses [18]. Neuromuscular blockade (pancuronium 0.1 mg/kg, IV) ﬁxed the eyes in primary gaze;
positive pressure ventilation with 100% oxygen was provided.
Ventilation and anesthesia were adjusted every 15 min to
maintain heart rate and venous blood gas measures in normal
range.
Scanning was conducted on a 3.0 Tesla Siemens Trio (http://
www.siemens.com) using a standard head coil. Echoplanar
images (3 3 3 3 3 mm resolution over 30 slices at TR ¼ 3 s)
were obtained during six seven-minute scans, as was a highresolution (0.4 3 0.4 3 1 mm) MPRAGE anatomical image.
Visual stimulation was 21 s of an 18-degree high-contrast
reversing (5 Hz) annular checkerboard (0.2–0.6 cycles per
degree) with a maximum luminance of 2.8 log cd.m2,
alternated with equivalent periods of darkness. The stimulation parameters were guided by a previous canine fMRI study
[19].
Data preprocessing and statistical analysis were performed
as previously described [20,21]. As the canine hemodynamic
response function (HRF) could not be speciﬁed a priori, a

Methods
Animals and Gene Therapy
A total of eight dogs participated in a total of 12 sessions
(Table 1): two normal animals and six RPE65-mutant dogs.
Animals were examined at a younger (,1 y) or older (1 y or
greater) treatment age, crossed with a shorter (1–3 mo) or
longer (18–30 mo) duration of treatment prior to MRI
scanning. Therapy was delivered by subretinal injection of
adeno-associated viral vector carrying the wild-type RPE65
[1,2]. One of the mutant animals served as a treatment control
and received a subtherapeutic dose (viral titer reduced by
four orders of magnitude [13]). A total of three mutant
animals were studied before and after therapy. All procedures
received institutional approval.

Electroretinogram
Dark-adapted dogs, premedicated (acepromazine and
atropine) and anesthetized (intermittent IV ketamine), had
full-ﬁeld electroretinograms (ERGs) using published methodology [1,2]. Dark-adapted luminance-response functions were
obtained with ﬂash stimuli spanning ;5 log units (2.5 to þ2.2
log scot-cd.s.m2). Threshold and amplitude parameters
derived from the ERG were used to compare animals. ERG
threshold was deﬁned as the intensity that evoked a criterion
PLoS Medicine | www.plosmedicine.org
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participant. Results for RPE65-LCA patients were compared
to published norms [26] and controls (n ¼ 4).
Voxel-based morphometry [27] was performed upon the
T1-weighted MPRAGE images from patients and controls to
identify areas of anatomical difference between populations.
Preprocessing of anatomical images included automated
skull-stripping, nonlinear noise reduction, and tissue segmentation (http://www.fmrib.ox.ac.uk/fsl) [28]. Each brain
volume was computationally ‘‘warped’’ to a representative
brain, and the log of the determinant of the Jacobian matrix
at each point used to index the degree of expansion or
contraction [29]. In addition to a whole-brain comparison
between the populations, a focused analysis was conducted
within anatomically deﬁned ROIs, further constrained by
tissue type identiﬁed by automated tissue segmentation.
Inﬂated cortical representations were created using commercial software (BrainVoyager).

two-stage analysis was undertaken. First, a Fourier basis set
(fundamental frequency and three harmonics) was used to
model evoked responses to light stimulation for each animal.
The combined explanatory power of these covariates was
evaluated with an F-test [20].
An average canine HRF (and its ﬁrst derivative) was then
obtained from the evoked response within the lateral gyrus
across animals and used in covariate construction for a group
analysis. Anatomical registration was accomplished via transformation using SPM2 to a digital canine atlas [22]. No
difference in response between the left and reﬂected right
hemisphere was seen at the map-wise level in a group analysis,
consistent with binocular successful gene therapy and the
visual stimulation protocol we used. Consequently, the data
from the two hemispheres were averaged. Group results were
displayed upon an inﬂated cortical atlas, created using the
BrainVoyager software (http://www.brainvoyager.com).
Regions of interest (ROIs) within the lateral gyrus,
suprasylvian cortex, and lateral geniculate nuclei were
deﬁned using the main effect of visual stimulation across
all animals. The average amplitude and volume of tissue with
a response to visual stimulation (.0.1% change in the
canine HRF and ﬁrst derivative covariates [23]) was obtained
for each animal for each ROI. Random-effects comparisons
between the groups were conducted with two-sample, onetailed t-tests.

Functional Image Processing
Stimulus-induced changes in the BOLD signal were
modeled as a ‘‘boxcar’’ covariate, convolved with a population hemodynamic response function [20]. The percentage
signal change associated with a level of visual stimulation
(derived from the beta value-modeling BOLD signal change
relative to the intercept term) was obtained for each voxel for
each scan, and the average signal change across population
(RPE65-LCA patients or control individuals) calculated for
each voxel in standard space. As was the case for the canine
data, the absence of map-wise differences in hemispheric
response allowed us to collapse the data from the two
hemispheres to create a single, pseudohemisphere. A second
analysis evaluated the degree of functional response observed
across a range of stimulus intensities. A region of interest was
deﬁned in standard space to include all posterior visual areas
(both primary and association cortices). For each level of
stimulation the tissue volume that demonstrated a strong
response to visual stimulation (.2% signal change) was
identiﬁed.

Human Participants
RPE65-LCA patients (n ¼ 6; ages 18–23 y), and control
individuals (n ¼ 8; ages 20–42 y) participated in the studies.
RPE65 mutations have been previously reported for the six
patients [12,24]. All patients were evaluated clinically and
with visual and retinal studies using published methods
[10,12,25]. An additional 28 control participants (ages 18–23
y) provided whole-brain T1-weighted images for the group
analysis of cortical morphology. Informed consent was
obtained, and procedures followed institutional guidelines
and the Declaration of Helsinki.

BOLD fMRI Scanning Protocol

Results
RPE65 Gene Therapy Restores Retinal and Subcortical
Function to RPE65-Mutant Dogs

A 3.0 Tesla Siemens Trio and an eight-channel head coil
were used for scanning. Functional scanning was performed
following acquisition of anatomical images (during which the
participant remained dark-adapted). A white rectangular
screen (subtending 278 3 188) of uniform luminance and
ﬂickering at 5 Hz was presented for 30 s periods, alternated
with 30 s periods of darkness. This wide-ﬁeld unstructured
stimulus was chosen to obviate the need for ﬁxation in this
population of patients with abnormal eye movements and
severe vision loss. Stimulus intensity was varied from low to
high over a 7.2 log unit range by sequentially removing
neutral density ﬁlters from the light path (maximum
unattenuated screen luminance, 3.75 log cd.m2). At least
two scans were performed at each stimulus intensity.

RPE65-mutant dogs have severe impairment of retinal and
subcortical responses (Figure 1). BOLD fMRI data, acquired
through the eye [30] showed no signiﬁcant response to light
stimulation (Figure 1B). ERG response thresholds were
elevated by 3–4 log units (Figure 1C), and the normal
reﬂexive contraction of the pupil in response to light was
nearly absent (Figure 1D). Retinal gene therapy improved the
three measures (Figure 1B–1D). BOLD fMRI signal showed
retinal responses to light after treatment. ERG thresholds
returned to near normal levels and waveforms increased in
amplitude (consistent with a focal area of retina undergoing
treatment [2,13]). Pupillary responses to light also recovered
following treatment, indicating that brainstem visual pathways can function following retinal gene therapy. To
determine whether successful retinal treatment was associated with a recovery of cortical visual responses despite
prolonged visual deprivation, we next obtained BOLD fMRI
data in wild-type dogs and then RPE65-mutant dogs with and
without treatment.

Anatomical Image Analysis
Interpial optic nerve diameter was measured on a highresolution (0.375 3 0.375 3 2.2 mm) T2-weighted anatomical
image by one of us (MK), blinded to the assignment of image
to population. Measurements from each eye at three
locations (1 cm posterior to the globe, anterior to the orbital
apex, and at the nerve midpoint) were averaged for each
PLoS Medicine | www.plosmedicine.org

1119

June 2007 | Volume 4 | Issue 6 | e230

Dog and Human Visual Brain in RPE65-LCA

Figure 1. Retinal and Subcortical Responses in RPE65-Mutant Dogs Restored with Gene Therapy
(A) Visual system structures involved in the measured responses are shown: EWN, Edinger-Westphal nucleus; LGN, lateral geniculate nucleus; CTX,
striate and parastriate cortex.
(B) Retinal blood flow responses to visual stimulation are presented. Shown is the average BOLD fMRI response (6 standard error of mean in gray) to
visual stimulation obtained from the eyes of an affected animal (BR235) pre- (filled symbols) and post-treatment (unfilled symbols). After treatment,
light stimulation evokes a change in blood flow within the retina, which was absent prior to therapy. The initial negative response of the signal is a
consequence of the brief period of stimulation used (21 s) in the face of a very long integration time (.40 s), which has been observed in retinal
hemodynamic responses [30]. On the left side are coronal slices through the eye obtained pre- (top) and post-treatment (bottom). Signal responses
after treatment (thresholded F . 3.5) are seen along the posterior curvature of the globe. Signal loss from susceptibility artifact from frontal sinuses
masks any responses from more anterior areas of the eye.
(C) Retinal electrophysiology by ERG is shown. Left panels compare waveforms evoked by increasing intensities of light in wild-type (WT) and RPE65mutant dogs (untreated and treated). Raw (gray) and filtered (black) waveforms are displayed for the mutant dogs. Arrows show ERG b-wave
thresholds. Right panels show threshold and amplitude parameters in RPE65-mutant dogs 3 mo after treatment (unfilled symbols) compared to wildtype (squares), untreated (filled symbols), and after a subtherapeutic dose (BR239, stars) dogs (vertical dotted lines connect eyes with pre- and posttreatment evaluations; gray region defines mean þ 2 SD of the ERG parameter in untreated RPE65-mutant eye).
(D) Brainstem responses using the TPLR in BR164 pre- and 1 mo post-treatment (video frames show the pupil before and 0.6 s after a 0.6 log scot-cd.m2
stimulus; pupillary margin delineated). Pupillary contraction amplitude and timing in this eye post-treatment (middle panel; unfilled triangles) was
within normal limits (gray band). Threshold and amplitude parameters (right panel) show treatment success in RPE65-mutant eyes after gene therapy
compared to untreated/pretreatment results.
doi:10.1371/journal.pmed.0040230.g001

Functional MRI Identifies Striate and Extrastriate Visual
Cortex in Normal Canine Brain

dogs in posterior cortical areas (Figures 2 and 3). The
anatomical site of activity included the lateral gyrus (the
posterior, midline structure adjacent to the interhemispheric
ﬁssure), as well as a smaller response within the more
laterally located ectomarginal and suprasylvian areas. These

Neural responses to light stimulation in wild-type dogs
using fMRI under the experimental conditions were ﬁrst
established. FMRI responses to light were observed in normal
PLoS Medicine | www.plosmedicine.org
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locations of activity are comparable to the visual areas found
in the cat [31,32], with the lateral gyrus containing striate
and parastriate cortex (areas 17 and 18), and the distinct
laterally located cortical response corresponding to extrastriate visual areas that may be specialized for motion
perception [31].

Retinal Gene Therapy Restores Canine Cortical Visual
Responses
RPE65-mutant dogs prior to treatment showed no signiﬁcant cortical or subcortical responses to light stimulation
using the conventional map-wise threshold along the visual
pathway with fMRI. As the integrated luminance of the fMRI
stimulus was within an order of magnitude of the ﬂash ERG
stimulus that evoked criterion responses in untreated RPE65mutant dogs (Figure 1C), we asked whether cortical responses
were present but too small to detect. Upon lowering
statistical thresholds (Figure 2), pretreatment animals showed
a weak response eccentrically located within the lateral gyrus;
this response was markedly reduced compared to control
activation at the same threshold. Group analysis conﬁrmed
the presence of minimal but detectable pretreatment
responses within the lateral gyrus (Figure 3).
Following successful gene therapy in ﬁve animals, signiﬁcant cortical activation within the lateral gyrus was observed
(Figures 2 and 3). In two animals, the extent of the recovered
response approached that seen in wild-type controls, despite
the limited area of retina that underwent treatment. As the
retinal treatment targeted the area centralis [1,2,13], cortical
magniﬁcation may explain this observation. In two treated
animals, signiﬁcant activity was located within the suprasylvian and ectosylvian cortex, which corresponds to extrastriate cortex in control animals. Subtherapeutic treatment
(BR239, Table 1) showed no increase in cortical response
(unpublished data).
A group analysis of the ﬁve treated animals further
illustrates these ﬁndings (Figure 3; Table 2). While minimal
responses were seen within the lateral gyrus prior to
treatment, a marked increase in response was seen following
treatment. Within the lateral gyrus (corresponding to striate
and parastriate cortex), the treated animals had signiﬁcantly
greater responses to light than were seen in the affected
animals prior to treatment (Figure 3B; t-test [7 df] ¼ 11.1; p ,
0.001). The group analysis of treated animals also conﬁrmed
increases in the extent of response within the suprasylvian
cortex (t[7] ¼ 2.5; p ¼ 0.043) and lateral geniculate nucleus
(LGN) (t[7] ¼ 3.8; p ¼ 0.007). Analyses conducted upon the
average amplitude of response within each region, as opposed
to spatial extent, yielded similar results (greater response for
treated compared to untreated RPE65 dogs: lateral gyrus t[7]
¼ 5.0, p ¼ 0.002; suprasylvian t[7] ¼ 2.3, p ¼ 0.056; LGN t[7] ¼
2.4, p ¼ 0.046).
Normal animals showed somewhat greater amplitude and
extent of neural responses compared to treated animals
(Table 2). The amplitude of response within the lateral gyrus
and LGN was signiﬁcantly greater in control as compared to
treated animals in a map-wise ﬁxed effects analysis (unpublished data). There was a trend toward a greater extent of
cortical response within the suprasylvian area in the normal
animals in the random-effects analysis (Table 2).
Dogs were studied at shorter or longer times following
treatment (Table 1). Recovery of cortical responses was
PLoS Medicine | www.plosmedicine.org

Figure 2. fMRI Responses in RPE65-Mutant Dogs before and after Gene
Therapy
Three coronal slices through the brain are shown, including both the
lateral gyrus and extrastriate cortical areas (located within the marginal
and ectomarginal sulci). Red and yellow indicate the location of
significant responses to light stimulation. Top row: visual responses in
a wild-type (WT) dog. Middle three rows: pre- and post-treatment data
from an RPE65-mutant dog. Post-treatment data were obtained during
two separate sessions separated by 1 mo and continue to show WT-like
responses in both sessions. Responses within the lateral gyrus pretreatment were seen at a lowered statistical threshold. Bottom row: responses
in an animal studied 18 mo after treatment.
doi:10.1371/journal.pmed.0040230.g002

observed as soon as 1 mo after therapy, and results were
reproducible when studied a second time, 1 mo later (Figure
2). As retinal transgene expression with AAV2 vectors takes
approximately two to four weeks following treatment [33],
this result indicates that cortical neurons recovered responsiveness quite rapidly following restoration of retinal
function. Restored cortical responses were also persistent,
in that they were observed in animals treated 18–30 mo
earlier (Figure 2). The presence of cortical responses in
animals treated at 1 y and 4 y of age begins to answer an
important question about effect of age at time of treatment.
Further studies in a larger series of animals are warranted.
1121
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Figure 3. Cortical Responses in RPE65-Mutant Dogs (Analyzed as a Group) before and after Treatment Compared to Normal Dogs
(A) Areas of cortical activation to visual stimulation are shown in red and yellow on the inflated cortical surface from medial and lateral views (inset
shows surface rendering of the initial, folded canine brain). Shades of gray indicate gyral (light) and sulcal (dark) cortex, and the position of three sulci
(m, marginal; e, ectomarginal; s, suprasylvian) are marked for reference. In untreated animals (n ¼ 3), a small response within the lateral gyrus is present.
After treatment (n ¼ 5), robust responses in both the lateral gyrus (striate and parastriate cortex) as well as in more laterally located extrastriate areas are
seen. The position of the lateral gyrus region of interest examined in (B) is outlined in black on the medial surface of the data from the control animals (n
¼ 2). At bottom left the shape of the average canine hemodynamic response (solid white) and its first derivative (dashed white) to 21 s of visual
stimulation (yellow bar) are shown.
(B) The extent of response within the lateral gyrus region of interest is plotted for treated (unfilled circles), compared to wild-type (squares), and
untreated (filled circles) dogs. Vertical dotted lines connect results with pre- and post-treatment evaluations. There is a significant increase in cortical
response to light following gene therapy.
doi:10.1371/journal.pmed.0040230.g003

Humans with RPE65-LCA Show Profound Retinal and
Subcortical Dysfunction

photoreceptor layer into adulthood [12]. Patient 6 (P6), age
23 y, exempliﬁes the retained photoreceptor layer structure
seen in humans with RPE65 mutations (Figure 4B, left). The
retinal output is conducted through axons from retinal
ganglion cells, and these axons form the optic nerve. The
axon ﬁber-layer thickness measured in an annular region
surrounding the intraocular optic nerve head fell within the

LCA due to RPE65 mutations is characterized by marked
visual loss from early life. Perceptual thresholds in response
to full-ﬁeld light stimuli are, on average, at least 4 log units
elevated (Figure 4A). The retina in RPE65-LCA can retain
normally organized laminar architecture with a measurable

Table 2. Canine fMRI Cortical Activation
Measure

Dogs

Treatment Status

Volume (cm3)

RPE65

Untreated (n ¼ 3)

Lateral Gyrus

p-Value

1.3 6 0.6

b

Suprasylvian
0.5 6 0.2

8.2 6 0.8

Amplitude (% change)

RPE65

10.1 6 1.4
Untreated (n ¼ 3)
Treated (n ¼ 5)a

0.42 6 0.18

0.00 6 0.03
0.056

0.10 6 0.06
0.14

Normal (n ¼ 2)

0.25
2.1 6 0.6

0.02 6 0.05

0.18 6 0.06

0.046
0.05 6 0.05

0.2
0.20 6 0.11

b

0.007

0.056

0.002

p-Value

1.6 6 0.8

2.3 6 0.5

0.07 6 0.06

LGN
0.3 6 0.3

1.2 6 0.7
0.14

Normal (n ¼ 2)

b

0.043

,0.001
Treated (n ¼ 5)a

p-Value

0.16
0.28 6 0.17

Results specified as mean 6 SD.
a
We averaged two post-treatment results from BR235; results from BR239, treated with a subtherapeutic dose, were not included.
b
Comparison between groups in rows above and below the p-Value.
doi:10.1371/journal.pmed.0040230.t002
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the fovea for normal (top) and patient 6 (P6) (bottom). PR, photoreceptor
layer; F, fovea; T, temporal; N, nasal. (Right) Polar plot of nerve fiber layer
thickness along a circle (diameter 3.4 mm) centered on the optic nerve
head is shown. Gray area, normal mean 6 2 SD; S, superior; I, inferior.
(C) Retinal electrophysiology by ERG is shown. Left: ERGs to white flashes
in the dark- and light-adapted states for patient 2 (P2) and an agematched normal are shown. Stimulus intensities for dark-adapted
responses span 5.2 log units. Patient 2 (P2) shows recordable responses
only to the higher stimulus intensities, and amplitudes are severely
reduced (note 10-fold change in amplitude scale). Calibration bars are in
lV for amplitude and ms for time; stimulus onset is at trace onset. Right:
Summary results from patients (circles) show dark-adapted threshold
elevations in excess of 3.5 log units from normal (square, mean 6 2 SD).
nd, nondetectable.
(D) Brainstem responses using TPLR in normal participants and RPE65LCA patients are shown. Left: Change in horizontal pupil diameter
evoked by light stimulus in a normal individual (unfilled squares)
compared to patient 3 (P3) (filled symbols) is presented. The smaller and
slower pupil response in the patient resembles the normal response to a
5.7 log unit dimmer flash (gray line). Response thresholds were
determined at 0.6 s (vertical dashed line). Inset: Images of the pupil
before and 0.6 s after a stimulus (2.3 log scot-cd.m2; 100 ms; green).
Calibration bar, 6 mm. Right: Summary results from patients (circles)
showing threshold elevations in excess of 4 log units from normal
(square, mean 6 2 SD).
doi:10.1371/journal.pmed.0040230.g004

normal range in patient 6 (P6) (Figure 4B, right) and in the
other patients (unpublished data). Retinal photoreceptor and
bipolar cell function, as quantiﬁed by the ERG, is severely
impaired in animals with RPE65 deﬁciency [1,2,8], and this
was also evident in the retinas of humans with RPE65-LCA.
Normal human retinas respond to increasing stimulus
intensity with increased ERG signal amplitude (Figure 4C).
RPE65-mutant human retinas (ﬁve ERG recordings available)
were either nonresponsive to all stimuli (n ¼ 3) or only
responded at maximal stimulation (n ¼ 2). Recordable b-wave
(representing bipolar cell activity) amplitudes were, on
average, about 3% of normal (8.9 and 13.2 lV for patient 2
[P2] and patient 5 [P5], respectively; normal mean, 440 lV,
standard deviation [SD] 92 lV, n ¼ 50). ERG thresholds were
at least 3.7 log units elevated from normal. Pupillary
constriction in response to a short-duration light stimulus
quantiﬁes transmission from retina to brainstem nuclei.
Pupillometry abnormalities in RPE65-deﬁcient animals have
been consistent with the profound retinal defect, showing 4–5
log units of threshold elevation [1,10]. All six patients with
RPE65 mutations had measurable but markedly abnormal
pupillary light reﬂexes (Figure 4D); thresholds ranged from
5.3 to 7.2 log units elevated above mean normal [10].

RPE65–LCA Patients Can Have Near Normal Visual
Pathway Anatomy
Does severe early visual deﬁcit in humans with RPE65
mutations lead to atrophy of the orbital optic nerves and
thinning of occipital lobe gray and white matter as reported
in forms of early blindness [16,17]? High-resolution (375 lm)
images were obtained through the intraorbital optic nerves,
and the average interpial diameter was measured (Figure 5A).
RPE65-LCA patients and age-matched control individuals
both had an average optic nerve diameter of 3.2 mm, in
agreement with published normal data using high-resolution
MRI and histological examination [26].
We next examined if alterations in cerebral anatomy are
present in humans with RPE65-LCA. The 1-mm resolution
whole-brain anatomical images obtained from patients with
RPE65-LCA were compared to a population of age-matched

Figure 4. Retinal and Subcortical Dysfunction in Human LCA Due to
RPE65 Mutations
(A) Shown are visual thresholds to a full-field stimulus (white, 200 ms) in
normal participants (62 SD) and RPE65-LCA patients showing abnormalities of at least 4 log units.
(B) Retinal structure by optical coherence tomography is shown. (Left)
Cross-sectional retinal images are along the horizontal meridian through
PLoS Medicine | www.plosmedicine.org
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patients and controls [16,17] and alterations of the structure
of the LGN [17,34], we conducted a more focal test. The LGN
was deﬁned in the registered space, and the mean Jacobian
measure for this volume of interest was obtained for the
controls and patients. No difference in anatomical structure
was observed (Figure 5B). Next, the white matter within the
occipital lobe underlying early visual areas (i.e., adjacent to
the collateral sulcus) was identiﬁed. The mean Jacobian
measure from this area for two of the RPE65-LCA patients
fell outside the range of measurements from normal controls
(Figure 5B, right panel), and the population mean was slightly
more negative (t[31] ¼ 3.0; p ¼ 0.005), indicating a small degree
of occipital white matter atrophy in the patients as compared
to control. While present, this subtle change stands in
contrast to the marked reduction in white matter volume
seen in patients with early blindness from other causes [17].

RPE65 Human Cortex Fully Activates to Suprathreshold
Visual Stimulation
Does a profoundly insensitive retina from early life in
humans with RPE65 mutations lead to reduced extent of
cortex devoted to visual processing? This would be the
prediction from the literature on effects of visual deprivation
in animals [35] and functional MRI scan results in a patient
following reversal of longstanding anterior-segment ocular
disease [15]. Cortex deprived of stimulation from its primary
modality could become instead responsive to alternative
sensory modalities [36]. We tested this notion by determining
with fMRI the extent of visual cortex responsive to visual
stimulation in RPE65-LCA patients. Given the measurable
light perception in this population, we expected to ﬁnd at
least some cortical response to stimulation (although it is
theoretically possible that brightness detection could be
mediated on a subcortical basis).
First, we used a stimulus that was about 1 log unit brighter
than visual threshold in RPE65-LCA patients and compared
the cortical responses to those of visually normal individuals
using the same stimulus (Figure 6A; Table 3). Data from 28
scans (56 cortical hemispheres) were combined across
participants. Control individuals showed a large extent of
posterior occipital and temporal cortex that had a response
(.0.5% BOLD fMRI signal change) to the visual stimulus.
This activation corresponds to the anatomical location of the
retinotopically organized early visual areas, as well as higherorder visual association cortex with coarse retinotopic
organization (e.g., form-responsive visual areas such as the
lateral occipital complex [37]). In the RPE65-LCA patient
group a greatly attenuated response, both in extent and
intensity, was seen. Only small patches of responsive voxels
were present within more distal (presumably peripheral)
portions of early visual areas. A whole-brain random-effects
analysis of these data conﬁrmed signiﬁcant differences in
amplitude of response throughout the posterior visual areas
(unpublished data).
The ﬁnding of reduced activation to this stimulus
prompted the question of whether this was the limit of
visually responsive cortex. A more suprathreshold stimulus
was then used. Data from 19 scans (38 cortical hemispheres)
were combined (Figure 6B; Table 3). For control participants,
the extent of response was comparable to that seen for the
lower level of stimulus intensity. In contrast, the RPE65-LCA

Figure 5. Visual Brain Anatomy in Human LCA from RPE65 Mutations
(A) Interpial optic nerve diameter for patients and controls is shown. Left:
Locations of optic nerve measurements were made for patient 3 (P3)
upon high-resolution T2-weighted images. The average of six measurements (three from each nerve) were obtained for each participant. Right:
Average optic nerve diameters for RPE65-LCA patients and controls is
shown. No population difference was observed.
(B) Whole brain morphometric analysis. Left: The T1-weighted anatomical
images from RPE65 patients and controls were warped to a representative template (top row). The (log) determinant of the Jacobian matrix
calculated during warping for each participant (bottom row) indexes the
degree to which cerebral tissue is smaller or larger than the template
image. No differences between patients and controls were present in a
whole brain analysis of these measures. A focused analysis was
conducted within the LGN and occipital lobe white matter, indicated
in yellow and red on the registered anatomy. Also shown is the y- or zposition (mm) of each slice relative to the anterior commissure. Right:
The average (log) Jacobian measure within the regions of interest for
RPE65-LCA patients and controls is shown. Measures were slightly, but
significantly, smaller for patients within occipital white matter, indicating
relative atrophy.
doi:10.1371/journal.pmed.0040230.g005

normal individuals (n ¼ 28). The analysis included both
cortical gray and white matter as well as subcortical
structures (such as the LGN) (Figure 5B). No signiﬁcant
differences between the two populations were found at the
map-wise level (p . 0.4).
It is possible that focal anatomical differences between the
two populations exist, but that our test was insufﬁciently
powered to identify this difference while controlling the false
positive rate across the entire brain volume. Given previous
reports of differences in early visual areas between early blind
PLoS Medicine | www.plosmedicine.org
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Table 3. Human fMRI Results for Cortical Activation Volume
(cm3)
Participant

Lower Light
Intensity

p-Value

Higher Light
Intensity

p-Value

RPE65a
Normalb

8.8 6 1.2
29.7 6 8.3

,0.001

41.2 6 11.1
48.8 6 3.1

0.2

Results specified as mean 6 SD.
a
n ¼ 3 for lower light intensity, n ¼ 5 for higher light intensity.
b
n ¼ 7 for lower light intensity, n ¼ 3 for higher light intensity.
doi:10.1371/journal.pmed.0040230.t003

intensities following dark adaptation. Prior studies have
demonstrated a correspondence between BOLD fMRI response functions and psychophysical performance (e.g., in the
domain of contrast sensitivity [38]). Here, the lowest level of
stimulation presented was designed to be near the perceptual
threshold of normal individuals and thus several log units
below threshold for people with RPE65-LCA (Figure 4A).
Figure 6C plots the volume of cortical tissue that demonstrated a robust response to visual stimulation in control
individuals and RPE65-LCA patients. For control participants, the lowest light stimulus presented (7.2 log units below
maximum 0, Figure 6C) was associated with a small but
signiﬁcant neural response within visual areas. The volume of
cortical tissue with a substantial response to stimulation
increased monotonically with stimulus intensity. In contrast
cortex of patients with, RPE65-LCA showed no measurable
neural response to lower intensity stimuli that evoked neural
responses in control participants. At 3 log units below
maximum intensity, cortex of RPE65-LCA patients showed
a measurable response, although it was on average one-third
the size of that in control individuals. With increasing
intensity of light stimulation, the cortical response from
patients with RPE65-LCA grew, reaching similar volumes as
in normal controls at the maximum intensities used in the
study. At the maximum level of stimulation achieved in each
group, there was no difference in the extent of cortical
response (t[7] ¼ 1.4; p ¼ 0.2).

Figure 6. Mean Cortical Signal Change in Response to Visual Stimulation
in Human RPE65-LCA (n ¼ 6) and Control Populations (n ¼ 8)
(A and B) The BOLD fMRI response is shown for each population at two
stimulus intensities: (A) 3 log and (B) at/near maximum (between 1.2
log and 0 log). The areas of response are displayed upon a digitally
inflated right hemisphere. Sulci are indicated in dark gray and gyri in
light gray. (Insets) The general position of several retinotopic and higherorder visual areas, derived from data from control participants, is shown.
Visual area nomenclature is as published [37].
(C) Cortical activation as a function of stimulus luminance is presented.
The volume of posterior cortical tissue demonstrating a substantial
(.2%) response shows a sigmoidal relationship to the strength of visual
stimulation in normal controls and in patients. A Hill function (gray
smooth lines) is fit by eye to the data points corresponding to each
participant.
doi:10.1371/journal.pmed.0040230.g006

Discussion
Congenitally blind RPE65-mutant dogs recovered responses within cortical visual areas after retinal gene therapy.
Recovery was present even in a dog treated at 4 y of age.
These results are concordant with demonstrations of recovery at retinal and subcortical levels [1,2,39,40] and relate well
to the ﬁndings of improved visual evoked potentials and
simple visual behavioral tasks in dogs and mice [1,11,39–41].
RPE65 deﬁciency essentially causes severe binocular light
attenuation to the visual system, and a comparison to the
extensive literature on cortical effects of early visual
deprivation is of interest (reviewed in [42,43]). Visual
deprivation in animals shortly after birth leads to a dramatic
reduction of visually responsive neurons within cortical visual
areas. The timing and type of deprivation affects the
character and severity of alteration of cortical function [42–
44]. Binocular eyelid suture, which produces modest light
attenuation but severe form deprivation, produces greater

patients demonstrated markedly increased cortical activation
in response to the stronger stimulus. Notably, for the stronger
stimulus, RPE65-LCA patients showed a cortical area responsive to visual stimulation comparable to that in controls,
involving not only calcarine cortex but also dorsal and ventral
areas normally devoted to extrastriate visual processing. A
random-effects whole-brain statistical comparison between
the controls and patients did not reveal any signiﬁcant mapwise differences between the groups at this stimulation level.
To characterize more precisely the cortical responses to
visual input in humans with RPE65-LCA, we obtained fMRI
measures of neural activity in response to different light
PLoS Medicine | www.plosmedicine.org
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visual input in RPE65-LCA patients is sufﬁcient for cortical
development. The relatively preserved retinal structure [12],
limited but detectable retinoid cycle activity [49], and a range
of light level exposures during infancy and childhood may be
sufﬁcient to maintain normal postretinal anatomy and
function, or possibly extend cortical plasticity into adulthood. A few case reports have examined recovery of vision in
adulthood following relatively late treatment of ophthalmic
disease, typically lens or corneal opacities. In one particularly
well-studied case, correction of anterior segment disease in
adulthood resulted in limited recovery of vision and markedly
reduced cortical responses to visual stimuli, particularly in
extrastriate areas [15]. Indeed, persistent deﬁcits in integrative visual function are seen even when bilateral cataracts are
treated in childhood [50], although there is recent intriguing
evidence that recovery of some higher-level visual function is
possible with adult treatment [51].
Our results do not necessarily predict recovery of higherlevel visual function. Although a normal extent of cortex
responded to visual stimulation, we are unable to state if
cortical organization for vision is intact beyond elementary
luminance representation. It is encouraging, however, that
activity within ventral cortex normally associated with form
processing is present, as this was not found in the patient with
severe early anterior-segment pathology, even after it was
corrected [15]. In summary, the evidence for cortical functional recovery following retinal gene therapy in the RPE65mutant dog, taken together with relatively preserved cortical
structure and function of humans with RPE65 mutations,
provides increased optimism regarding potential for recovery
of functional vision in humans with RPE65-LCA, whether
treatment is by gene replacement, pharmacological bypass
[52], or visual prostheses [53].

abnormalities in cortical physiology than an equivalent
period of dark rearing [45]. The standard model is that early
visual experience during a critical period of neuronal
plasticity deﬁnes the response properties of cortical visual
neurons, and that after this period these properties become
relatively immutable [43]. The 4-log-unit reduction in light
sensitivity from retinoid cycle blockade in RPE65 deﬁciency
likely falls between dark-rearing and lid-suture experimental
paradigms. The recovery we observed after retinal gene
therapy suggests that the visual cortex of the RPE65-mutant
dog remained receptive to increased visual input for over 4 y.
While there was a dramatic recovery of cortical responsiveness following gene therapy, differences in the amplitude of
neural response within the lateral gyrus remained between
controls and some treated animals. These differences may be
attributable to the retinal location and area treated and
possibly to an effect of visual deprivation. In addition to a
general decline in the responses of cortical neurons, visual
deprivation disrupts the normal functional architecture of
visual areas, including receptive ﬁeld organization, ocular
dominance, and direction selectivity [45,46]. These might
differ between normal and treated animals, even if cortical
extent and maximal magnitude of neural responses were
comparable. Although the precise functional organization of
cortical visual areas following treatment was not addressed in
the present work on the RPE65-mutant dog, it is worth noting
that some animals in our study recovered responses in cortex
normally devoted to extrastriate visual areas, suggesting
preserved higher-level visual function.
Human RPE65-LCA has captured international interest as
a potential target for a retinal gene therapy approach like
that used in the RPE65-mutant dog [12,47]. It is unknown,
however, whether LCA patients with severe visual loss from
birth have any receptivity of cortical substrates for restored
retinal input. The literature suggests that early blind patients
could show markedly abnormal anatomy in the postretinal
visual pathways. A diffusion tensor imaging study of early
blind patients demonstrated atrophic or absent optic nerves
and geniculocortical tracts [17], while a voxel-based morphometry analysis revealed atrophy of cortical gray matter in
early visual areas [16]. Optic nerve diameter was no different
from normal in patients with RPE65-LCA, and no alteration
of the LGN was found. While a small reduction in occipital
white matter was found in RPE65-LCA patients, the subtle
nature of this change suggests a difference from other early
blind individuals, despite sharing a severe impairment of
visual perception from infancy. Our ﬁnding of relatively
preserved postretinal structure may be related to the sparing
of retinal ganglion cells in humans with RPE65-LCA, as
compared to more destructive lesions affecting the neural
retina, thereby preventing the anterograde transneuronal
degeneration that accompanies destruction of these neurons
[48].
Cortical function was also expected to be abnormal in
RPE65-LCA, and we found abnormal cortical activation using
a light stimulus that was deﬁnitely suprathreshold. Yet, this
was not the limit of visually responsive cortex. Surprisingly,
an increase in stimulus intensity fully activated the cortex of
humans with RPE65-LCA. A neural luminance-response
function at the cortex of patients with RPE65-LCA supports
the notion that given sufﬁcient light stimulation, the cortex
can be activated normally. We speculate that during early life,
PLoS Medicine | www.plosmedicine.org
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Dog and Human Visual Brain in RPE65-LCA

Editors’ Summary
Background. The eye captures light but the brain is where vision is
experienced. Treatments for childhood blindness at the eye level are
ready, but it is unknown whether the brain will be receptive to an
improved neural message. Normal vision begins as photoreceptor cells in
the retina (the light-sensitive tissue lining the inside of the eye) convert
visual images into electrical impulses. These impulses are sent along the
optic nerve to the visual cortex, the brain region where they are
interpreted. The conversion of light into electrical impulses requires the
activation of a molecule called retinal, which is subsequently recycled by
retinal pigment epithelium (RPE) cells neighboring the retina. One of the
key enzymes of the recycling reactions is encoded by a gene called
RPE65. Genetic changes (mutations) in RPE65 cause an inherited form of
blindness called Leber congenital amaurosis (LCA). In this disease, retinal
is not recycled and as a result, the photoreceptor cells cannot work
properly and affected individuals have poor or nonexistent vision from
birth. Previous studies in dog and mouse models of the human disease
have demonstrated that the introduction of a functional copy of RPE65
into the RPE cells using a harmless virus (gene therapy) dramatically
restores retinal activity. Very recently, a pioneering gene therapy
operation took place in London (UK) where surgeons injected a
functional copy of RPE65 into the retina of a man with LCA. Whether
this operation results in improved vision is not known at this time.

normal dogs. The recovery of cortical responses was permanent and
occurred soon after treatment, even in animals that were 4 years old
when treated. Next, using structural MRI, the researchers studied human
patients with LCA and found that the optic nerve diameter in young
adults was within the normal range and that the structure of the visual
cortex was very similar to that of normal individuals. Finally, using fMRI,
they found that, although the visual cortex of patients with LCA did not
respond to dim light, its reaction to bright light was comparable to that
of normal individuals.
What Do These Findings Mean? The findings from the dog study
indicate that retinal gene therapy rapidly improves retinal, visual
pathway, and visual cortex responses to light stimulation, even in
animals that have been blind for years. In other words, in the dog model
of LCA at least, all the components of the visual system remain receptive
to visual inputs even after long periods of visual deprivation. The
findings from the human study also indicate that the visual pathway
remains anatomically intact despite years of disuse and that the visual
cortex can be activated in patients with LCA even though these people
have very limited visual experience. Taken together, these findings
suggest that successful gene therapy of the retina might restore some
functional vision to people with LCA but proof will have to await the
outcomes of several clinical trials ongoing or being planned in Europe
and the USA.

Why Was This Study Done? Gene therapy corrects the retinal defects in
animal models of LCA but whether the visual pathway from the retina to
the visual cortex of the brain can respond normally to the signals sent by
the restored retina is not known. Early visual experience is thought to be
necessary for the development of a functional visual cortex, so replacing
the defective RPE65 gene might not improve the vision of people with
LCA. In this study, the researchers have studied the visual cortex of
RPE65-deficient dogs before and after gene therapy to see whether the
therapy affects the activity of the visual cortex. They have also
investigated visual pathway integrity and responsiveness in adults with
LCA caused by RPE65 mutations. If the visual pathway is disrupted in
these patients, they reasoned, gene therapy might not restore their
vision.

Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040230.
 General information on gene therapy is available from the Oak Ridge
National Laboratory
 Information is provided by the BBC about gene therapy for Leber
congenital amaurosis (includes an audio clip from a doctor about the
operation)
 The National Institutes of Health/National Eye Institute (US) provides
information about an ongoing gene therapy trial of RPE65-Leber
congenital amaurosis
 ClinicalTrials.gov gives details on treatment trials for Leber congenital
amaurosis
 The Foundation Fighting Blindness has a fact sheet on Leber
congenital amaurosis (site includes Microsoft Webspeak links that
read some content aloud)
 The Foundation for Retinal Research has a fact sheet on Leber
congenital amaurosis
 Find more detailed information on Leber congenital amaurosis and
the gene mutations that cause it from GeneReviews
 WonderBaby, information for parents of babies with Leber congenital
amaurosis

What Did the Researchers Do and Find? The researchers used a
technique called functional magnetic resonance imaging (fMRI) to
measure light-induced brain activity in RPE65-deficient dogs before and
after gene therapy. They also examined the reactions of the dogs’ pupils
to light (in LCA, the pupils do not contract normally in response to light
because there is reduced signal transmission along the visual pathway).
Finally, they measured the electrical activity of the dogs’ retinas in
response to light flashes—the retinas of patients with LCA do not react
to light. Gene therapy corrected the defective retinal and visual pathway
responses to light in the RPE65-deficient dogs and, whereas before
treatment there was no response in the visual cortex to light stimulation
in these dogs, after treatment, its activity approached that seen in
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